This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Live Chat

Stocks in this article: AMRN SRPT DNDN VVUS SPPI ARNA MDVN INCY ONXX

BOSTON ( TheStreet) -- Welcome to Biotech Stock Live Chat: Hurricane Sandy edition.

First, let me say I hope everyone is safe and as comfortable as possible following a crazy day and night. Here just north and west of Boston, we managed to get through relatively unscathed but I know a lot of people without power or with significant damage to their homes. My sympathies.

U.S. stock markets are closed for a second straight day due to the storm, so while we're all sitting around (or taking a break from Sandy clean up) let's spend an hour or so talking biotech stocks and biotech investing.

The floor is yours. I'm happy to discuss Amarin (AMRN) and the outlook for the pending launch of its prescription fish-oil pill Vascepa. I know many of you are very bullish on Amarin's future so make your case here in the live blog.

Obesity drug stocks -- Vivus (VVUS - Get Report), Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX) -- are always a good topic.

Biotech earnings season has been interrupted due to the storm but we will get reports this week from Onyx Pharmaceuticals (ONNXX) and Medivation (MDVN), giving us the first peek at new cancer drug launches. Also scheduled to report: Vertex Pharmaceuticals (VRTX), Dendreon (DNDN), Spectrum Pharmaceuticals (SPPI - Get Report) and Incyte (INCY). Let's discuss.

Sarepta Therapeutics (SRPT - Get Report): Why is the stock down so much since early October? What are the chances for eteplirsen accelerated approval?

Let's chat about these stocks or any other biotech investing question you might have. Thanks for participating.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs